Table 1.

Studies Included in Analysis

Study No.	Cancer Site	Cancer Stage	Treatment	Phase	Enrollment Years	Prior Neuropathy Exclusion Level	No.
S9712	Lung	Poor-risk stage III NSCLC	Concurrent carboplatin+VP-16 and radiation followed by paclitaxel	II	1999-2000	None	11
S9900	Lung	Clinical stages IB-IIIA NSCLC	Surgery alone or surgery plus preoperative paclitaxel plus carboplatin	III	2000-2004	Grade ≥ 1	38
S9902	H&N	Metastatic/recurrent squamous cell carcinoma	Docetaxel plus carboplatin	II	2000	Grade ≥ 2	12
S9912	GYN	Optimally debulked stage II epithelial ovarian, primary peritoneal, or fallopian tube cancer	Intravenous paclitaxel, intraperitoneal cisplatin, intravenous liposomal doxorubicin, and intraperitoneal paclitaxel	II	1999-2005	Grade ≥ 2	13
S9914	Lung	Extensive small-cell lung cancer	Paclitaxel, carboplatin, and topotecan with G-CSF	II	1999-2001	Grade ≥ 1	21
S9916	GU	Advanced, hormone refractory prostate cancer	Docetaxel and estramustine v mitoxantrone and prednisone	III	2000-2003	None	188
S0003	Lung	Advanced NSCLC	Cisplatin, paclitaxel, tirapazamine v cisplatin, paclitaxel	III	2001-2002	Grade ≥ 2	101
S0007	H&N	Advanced/recurrent squamous cell carcinoma	Paclitaxel plus cisplatin and fluorouracil	II	2001-2003	Grade ≥ 2	16
S0009	GYN	Stage III and IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer	Neoadjuvant paclitaxel plus carboplatin v IV plus IP paclitaxel plus carboplatin	II	2002-2005	Grade ≥ 2	20
S0012	Breast	Inflammatory and locally advanced breast cancer	Standard doxorubicin and cyclophosphamide followed by weekly paclitaxel v weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel	III	2001-2005	None	23
S0022	Lung	Stage IIIB NSCLC	Concurrent cisplatin plus docetaxel and radiotherapy followed by consolidation docetaxel	II	2001-2002	Grade ≥ 1	12
S0023	Lung	Inoperable locally advanced stage III NSCLC	Cisplatin plus etoposide plus radiotherapy with consolidation docetaxel followed by maintenance therapy with ZA1839 or placebo	III	2002-2005	Grade ≥ 1	89
S0027	Lung	Advanced NSCLC in patients ≥ 70 years	Sequential vinorelbine and docetaxel	II	2001-2003	Grade ≥ 2	69
S0028	GU	Metastatic urothelial cancer in patients ≥ 70 years	Gemcitabine and paclitaxel	II	2001-2006	None	44
S0029	Breast	Metastatic breast cancer in patients ≥ 70 years	Single-agent docetaxel	II	2002-2005	None	12
S0032	GU	High-risk metastatic adenocarcinoma	Early oral estramustine, oral etoposide, and intravenous paclitaxel in combination with hormone therapy	II	2002-2005	None	11
S0102	Breast	HER-2 negative, stage IV	Docetaxel and vinorelbine plus filgrastim	II	2001-2003	Grade ≥ 2	13
S0219	GU	Nonmetastatic carcinoma of the bladder	Neoadjuvant gemcitabine, paclitaxel, and carboplatin with molecular correlates	II	2003-2006	None	31
S0221	Breast	Node-positive or high-risk node negative	Continuous schedule AC+G v 2-week schedule AC, followed by paclitaxel administered either every 2 weeks or weekly for 12 weeks	III	2003-2011	None	127
S0329	H&N	Recurrent/metastatic squamous cell carcinoma	Gemcitabine and paclitaxel combination administered every 2 weeks	II	2005-2006	Grade ≥ 2	23
S0421	GU	Advanced hormone refractory prostate cancer	Docetaxel and atrasentan v docetaxel and placebo	III	2006-2010	Grade ≥ 2	408
S0536	Lung	Advanced NSCLC	Combination carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab	II	2006-2007	Grade ≥ 2	33
S0819	Lung	Advanced NSCLC	Carboplatin plus paclitaxel or carboplatin plus paclitaxel plus bevacizumab with or without concurrent cetuximab	III	2009-2011	Grade ≥ 2	86

Abbreviations: AC, adriamycin and cytoxan; G; G-CSF; G-CSF, granulocyte colony-stimulating factor; GU, genitourinary; GYN, gynecologic; H&N, head and neck; IV+IP, intravenous and intraperitoneal; NSCLC, non–small-cell lung cancer; VP-16, etoposide.